Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh, Sirpa Leppä, Shinya Rai, Mehmet Turgut, Wojciech Jurczak, Matthew C Cheung, Ronit Gurion, Su-Peng Yeh, Andres Lopez-Hernandez, Ulrich Dührsen, Catherine Thieblemont, Carlos Sergio Chiattone, Sriram Balasubramanian, Jodi Carey, Grace Liu, S Martin Shreeve, Steven Sun, Sen Hong Zhuang, Jessica Vermeulen, Louis M Staudt, Wyndham Wilson, PHOENIX investigators, Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh, Sirpa Leppä, Shinya Rai, Mehmet Turgut, Wojciech Jurczak, Matthew C Cheung, Ronit Gurion, Su-Peng Yeh, Andres Lopez-Hernandez, Ulrich Dührsen, Catherine Thieblemont, Carlos Sergio Chiattone, Sriram Balasubramanian, Jodi Carey, Grace Liu, S Martin Shreeve, Steven Sun, Sen Hong Zhuang, Jessica Vermeulen, Louis M Staudt, Wyndham Wilson, PHOENIX investigators
Abstract
Purpose: Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL.
Patients and methods: Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free survival (EFS) in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup. Secondary end points included progression-free survival (PFS), overall survival (OS), and safety.
Results: A total of 838 patients were randomly assigned to ibrutinib plus R-CHOP (n = 419) or placebo plus R-CHOP (n = 419). Median age was 62.0 years; 75.9% of evaluable patients had ABC subtype disease, and baseline characteristics were balanced. Ibrutinib plus R-CHOP did not improve EFS in the ITT (hazard ratio [HR], 0.934) or ABC (HR, 0.949) population. A preplanned analysis showed a significant interaction between treatment and age. In patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS (HR, 0.579), PFS (HR, 0.556), and OS (HR, 0.330) and slightly increased serious adverse events (35.7% v 28.6%), but the proportion of patients receiving at least six cycles of R-CHOP was similar between treatment arms (92.9% v 93.0%). In patients age 60 years or older, ibrutinib plus R-CHOP worsened EFS, PFS, and OS, increased serious adverse events (63.4% v 38.2%), and decreased the proportion of patients receiving at least six cycles of R-CHOP (73.7% v 88.8%).
Conclusion: The study did not meet its primary end point in the ITT or ABC population. However, in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety. In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes. Further investigation is warranted.
Trial registration: ClinicalTrials.gov NCT01855750.
Figures
References
- Stewart BW, Wild CP: World Cancer Report 2014. Lyon, France, IARC Press, 2014.
- Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–1217.
- Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
- Tilly H, Gomes da Silva M, Vitolo U, et al: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v116-v125, 2015 (suppl 5)
- National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Non-Hodgkin's lymphoma, version 4.2014. Washington, DC, National Comprehensive Cancer Network, 2014.
- Borel C, Lamy S, Compaci G, et al. A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: Implication for survival. BMC Cancer. 2015;15:288.
- Nowakowski GS, Chiappella A, Witzig TE, et al. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016;12:1553–1563.
- McMillan A, Martin A, Haioun C, et al: Post relapse survival rates in diffuse large B-cell lymphoma. Blood 128:4204, 2016 (abstr 4204)
- Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–3537.
- Davies AJ, Barrans S, Maishman T, et al: Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (DLBL): a prospective randomised study stratified by transcriptome profiling: REMODL-B. Hematol Oncol 35:130-131, 2017 (abstr 121)
- IMBRUVICA (ibrutinib). Prescribing information. Horsham, PA, Janssen Biotech; Sunnyvale, CA, Pharmacyclics, 2018.
- IMBRUVICA (ibrutinib). Summary of product characteristics. Beerse, Belgium, Janssen Pharmaceutical NV, 2018.
- Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926.
- Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study. Lancet Oncol. 2014;15:1019–1026.
- Schaffer M, Chaturvedi S, Alvarez JD, et al. Comparison of immunohistochemistry assay results with gene expression profiling methods for diffuse large B-cell lymphoma subtype identification in matched patient samples. J Mol Biomark Diagn. 2018;9:2.
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
- National Cancer Institute Caner Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) v4.03. .
- Song Y, Chi GY. A method for testing a prespecified subgroup in clinical trials. Stat Med. 2007;26:3535–3549.
- Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796–1805.
- Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29:1822–1827.
- Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma in the elderly: A review of potential difficulties. Clin Cancer Res. 2013;19:1660–1669.
- Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–1407.
- Scheers E, Leclercq L, de Jong J, et al. Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: An open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015;43:289–297.
- Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123:958–965.
- Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36:1603–1610.
- Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35:2473–2481.
- Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241–246.
- Hamlin PA, Satram-Hoang S, Reyes C, et al. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: A Surveillance, Epidemiology, and End Results-Medicare analysis. Oncologist. 2014;19:1249–1257.
Source: PubMed